Registration Document 2005 - Total.com
Registration Document 2005 - Total.com
Registration Document 2005 - Total.com
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Note 32.6: IFRS restatements with an impact<br />
on the net in<strong>com</strong>e<br />
Note 32.6a: Amortization of goodwill<br />
Pursuant to IFRS 3 “Business <strong>com</strong>binations”, goodwill is no longer<br />
amortized. Instead, it is tested for impairment annually. The impact<br />
on 2004 net in<strong>com</strong>e is 161 million euros, due to the cancellation of<br />
goodwill amortization.<br />
Note 32.6b: Share-based payments<br />
The Group applies IFRS 2 “Share-based payments” as published<br />
by the International Accounting Standards Board (IASB).<br />
This standard applies to employee stock-option and share<br />
purchase plans and to capital increases reserved for employees<br />
retrospectively and not solely to the share transactions that were<br />
granted after November 7, 2002.<br />
These employee benefits are recognized as expenses with a<br />
corresponding credit to shareholders’ equity.<br />
The cost of options is valued according to the Black & Scholes<br />
method and allocated on a straight-line basis between the grant<br />
date and vesting date. For employee-reserved capital increases, the<br />
cost is immediately recognized as an expense.<br />
The 2004 net in<strong>com</strong>e is adjusted due to an expense relating to<br />
employee share option and purchase plans and to the employeereserved<br />
capital increase in 2003. The corresponding charge is<br />
estimated at approximately 138 million euros.<br />
Appendix 1 – Consolidated financial statements<br />
Notes to the consolidated financial statements 9<br />
Note 32.6c: Equity-method affiliates’ IFRS restatement<br />
This restatement primarily relates to the implementation of IFRS<br />
in the equity-method affiliates’ financial statements, Sanofi-Aventis<br />
and Cepsa.<br />
Within the financial statements prepared in <strong>com</strong>pliance with IFRS<br />
by Sanofi-Aventis, in-progress R&D costs of Aventis have been<br />
capitalized as at the date of the merger. According to French GAAP,<br />
the R&D costs were directly charged to expense. The impact of<br />
this restatement amounts to 746 million euros on the net in<strong>com</strong>e<br />
– Group share.<br />
The effect on net in<strong>com</strong>e of IFRS restatements related to<br />
inventories and share-based payments, as indicated previously,<br />
may change in the future depending on the volatility in prices of raw<br />
materials and specific provisions included within employee share<br />
purchase or option plans, respectively.<br />
TOTAL - <strong>Registration</strong> <strong>Document</strong> <strong>2005</strong><br />
223